AstraZeneca

AZN · LONDON

$171.49−$1.08 (−0.63%)TodayMarket closed · Oct 23, 7:51 PM ET

Prev close $172.57

Latest news

NewsOct 22, 1:08 PM ETVandana Singh
FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug
Press releaseOct 22, 8:10 AM ETBusiness Wire
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
NewsOct 20, 12:51 PM ETVandana Singh
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
Press releaseOct 20, 9:00 AM ETBusiness Wire
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
NewsOct 20, 5:29 AM ETAkanksha Bakshi
Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
NewsOct 19, 8:38 AM ETVandana Singh
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Press releaseOct 19, 7:00 AM ETBusiness Wire
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
NewsOct 15, 10:52 AM ETVandana Singh
AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
NewsOct 12, 9:21 AM ETVandana Singh
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
Press releaseOct 8, 9:00 AM ETPRNewswire
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Press releaseOct 5, 12:01 PM ETBusiness Wire
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
Press releaseOct 5, 7:00 AM ETBusiness Wire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
NewsOct 2, 9:28 AM ETVandana Singh
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Press releaseOct 2, 2:30 AM ETBusiness Wire
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Press releaseOct 2, 2:30 AM ETBusiness Wire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
NewsSep 30, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
Press releaseSep 29, 12:12 PM ETGlobe Newswire
High-Stakes October has these Biotechs Entering Crucial Stretch
NewsSep 29, 9:12 AM ETVandana Singh
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
NewsSep 29, 6:57 AM ETTanya Rawat
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
Press releaseSep 28, 5:30 PM ETBusiness Wire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
NewsSep 25, 7:05 AM ET
AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026
Press releaseSep 25, 7:00 AM ETBusiness Wire
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
NewsSep 22, 1:43 PM ETVandana Singh
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
NewsSep 18, 1:52 PM ETVandana Singh
This $3 Biotech Could Be Worth $11.45, Analyst Says
Press releaseSep 18, 8:00 AM ETBusiness Wire
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
NewsSep 17, 7:19 AM ET
Transcript: AstraZeneca Q2 2026 Earnings Conference Call
NewsSep 16, 1:38 PM ETVandana Singh
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
NewsSep 15, 7:39 AM ETAvi Kapoor
AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’
NewsSep 14, 9:39 AM ETVandana Singh
Cellectis Pivots to Gene Editing in Major Overhaul
NewsSep 14, 8:46 AM ETVandana Singh
Why Is AstraZeneca Stock Trading Higher Today?
Press releaseSep 13, 9:55 PM ETBusiness Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Press releaseSep 13, 9:47 PM ETBusiness Wire
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
NewsSep 9, 8:56 AM ETAvi Kapoor
Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock
Press releaseAug 19, 8:56 AM ETGlobe Newswire
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
NewsAug 3, 1:13 PM ETVandana Singh
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
NewsAug 3, 12:45 PM ETThe Arora Report
Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey Wrench
NewsAug 3, 8:42 AM ETKaustubh Bagalkote
Why Is Bristol-Myers Squibb Stock Surging Monday?
NewsAug 3, 8:27 AM ETRishabh Mishra
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
NewsAug 3, 8:01 AM ETAvi Kapoor
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
NewsJun 8, 1:02 PM ETVandana Singh
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
NewsOct 9, 12:00 PM ET
A Look Into AstraZeneca Inc's Price Over Earnings
NewsSep 4, 7:09 AM ETAvi Kapoor
AstraZeneca, Corning And More On CNBC's 'Final Trades'
NewsJul 2, 3:09 PM ET
Price Over Earnings Overview: AstraZeneca

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research

Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal

AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

10 Health Care Stocks With Whale Alerts In Today’s Session

High-Stakes October has these Biotechs Entering Crucial Stretch

AstraZeneca Invests in Summit Therapeutics after Year of Speculation

Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

This $3 Biotech Could Be Worth $11.45, Analyst Says

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Transcript: AstraZeneca Q2 2026 Earnings Conference Call

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’

Cellectis Pivots to Gene Editing in Major Overhaul

Why Is AstraZeneca Stock Trading Higher Today?

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey Wrench

Why Is Bristol-Myers Squibb Stock Surging Monday?

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

A Look Into AstraZeneca Inc's Price Over Earnings

AstraZeneca, Corning And More On CNBC's 'Final Trades'

Price Over Earnings Overview: AstraZeneca